Clinical Trials Logo

Urticaria clinical trials

View clinical trials related to Urticaria.

Filter by:

NCT ID: NCT05513001 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib

Start date: December 9, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.

NCT ID: NCT05510843 Terminated - Clinical trials for Chronic Cold Urticaria

A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria

Start date: September 6, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1b, open label, non-randomized, sequential dose-escalation, multicenter trial in adult patients with chronic cold urticaria.

NCT ID: NCT05497596 Recruiting - Urticaria Clinical Trials

The Association Between Human Microbiome and Vitamin D in Chronic Urticaria

Start date: August 2, 2022
Phase: N/A
Study type: Interventional

A double-blind study to evaluate the role of human microbiome and vitamin D in the development of urticaria.

NCT ID: NCT05496465 Active, not recruiting - Urticaria Clinical Trials

Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in Subjects With Frequent Urticaria Flares

Start date: July 28, 2022
Phase: Phase 2
Study type: Interventional

Determine the effect of ARS-1 on a patient reported pruritus/hive score

NCT ID: NCT05461456 Completed - Psoriasis Clinical Trials

Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%

ATOFEX-1
Start date: April 1, 2022
Phase: Phase 1
Study type: Interventional

The investigational lotion is envisaged as an short- and long term "Ease & Prevent" monotherapy for adults and children with mild to moderate eczema. With itch representing the most burdensome symptom in eczema, the main objectives with the lotion is fast and efficient itch relief, high tolerability, and high short- and long term safety. This phase 1 study aims to monitor skin tolerability, and how much of the active compound that is absorbed to the bloodstream.

NCT ID: NCT05405660 Active, not recruiting - Clinical trials for Chronic Inducible Urticaria

A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Start date: June 28, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Inducible Urticaria who remain symptomatic despite the use of H1-antihistamines.

NCT ID: NCT05373355 Completed - Clinical trials for Chronic Spontaneous Urticaria

Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.

Start date: May 10, 2022
Phase: Phase 1
Study type: Interventional

This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 36 subjects with moderate to severe Chronic Spontaneous Urticaria.

NCT ID: NCT05368285 Active, not recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Start date: May 19, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the clinical effect, the pharmacodynamics, the safety, and the pharmacokinetics of barzolvolimab (CDX-0159) in patients with Chronic Spontaneous Urticaria

NCT ID: NCT05335499 Recruiting - Clinical trials for Chronic Spontaneous Urticaria

A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

Start date: June 28, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of TAS5315 in chronic spontaneous urticaria patients with an inadequate response to H1-antihistamines

NCT ID: NCT05330637 Recruiting - Asthma Clinical Trials

Study on the Influence of Climatic and Environmental Factors on Respiratory Diseases in Sanya, Hainan Province, China.

Start date: March 3, 2022
Phase:
Study type: Observational

To investigate the Influence of Climatic and Environmental Factors on Respiratory or Allergic Diseases in Sanya.